|
Association of polymorphisms with tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatine and radiation: Pharmacogenetic analysis of ACCORD-12/PRODIGE-2 trial. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Celgene; Roche |
| |
|
Consulting or Advisory Role - Roche; Sanofi |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Boehringer Ingelheim; Merck Serono; Roche; Sanofi |
Consulting or Advisory Role - Boehringer Ingelheim; Merck Serono |